



Fax: 866-336-9530  
Toll Free: 1-866-DEO-9530  
E-mail: [investorinfo@deobiosciences.com](mailto:investorinfo@deobiosciences.com)  
[www.deobiosciences.com](http://www.deobiosciences.com)

*John F. Adamson, Jr.  
President & CEO*

March 14, 2022

Dear Investors and Followers:

I realize that we may say “thanks” a lot, but it’s only because we mean it. We can’t express our appreciation for your support enough. Before the Netcapital campaign closes, we wanted to share the limited plans and updates that we can under the crowdfunding rules.

### **Post Campaign Logistics:**

I shared in a previous update that we’re planning to conduct the initial R&D outside the Ithaca, New York campus: most likely in a leased lab facility in the Atlanta, Georgia metro area. Well, we’ve started investigating leasing and logistics options with a couple of local facilities that have good reputations and think that they may offer some good options. After determining what our final raise amount on Netcapital will be, we’ll be better positioned to talk numbers and terms with them. Additionally, we’ll need to hire some local technical talent, and conduct more field sourcing of fresh raw materials. In summary, there’s a lot of work ahead but we’re revising the project plan to accommodate a lower end-of-campaign budget.

### **Post Campaign Financing 2022**

We also previously disclosed that we will pursue supplemental investment outside Netcapital if we don’t reach our minimum raise goal. And even then, we will probably explore more financing before finishing the next planned work phase. The securities laws can be a little sticky about announcing specific future fundraising plans to the general public (which is where we are before this campaign officially closes), so we will not go into details.

We have received inquiries of interest from individual investors and offers of introduction to angel investor groups during this crowdfunding campaign. We’ve also been introduced to a few investment and partnering meeting opportunities, and will explore them for potential fits. For example, we’ve been invited to and will attend (virtually) the Emerging Medtech Summit event, taking place at Monarch Beach Resort, Dana Point, California this week. The annual event provides highly innovative start-ups with the opportunity to present their technology to venture capital funds, private equity funds, SPACs, and strategic investors so both parties can deal-make and collaborate. While we did not pursue a presentation opportunity this year, it still provides an opportunity to network and start relationships.

In terms of pitches to investor groups, we will pursue some other upcoming opportunities that we feel match our stage of development and area of technology more closely. We’ll share any developments for those later.

We just wanted to update you with some recent developments as we head into the last day of our Netcapital campaign.

Thank you again for being a visionary and fearless ground-floor partner in our journey! You all really came through. More to come. Until next time, be well.

A handwritten signature in black ink, appearing to be 'John A.', written in a cursive style.

John A. & Team DeoBioSciences